Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA

Scandinavian Journal of Immunology
Lucilla SteinaaSøren Mouritsen

Abstract

It is of major importance to overcome the immunological tolerance in attempts to generate efficient tumour vaccines. Here, we describe induction of autoantibodies and self-reactive CTL in three types of OVA-transgenic mouse strains, RIP-OVA(low), RIP-mOVA and RIP-OVA(HI) exhibiting varying levels of OVA expression and tolerance. This was achieved by immunizing with DNA constructs where a foreign T-helper epitope, P30 from tetanus toxin, was inserted into the OVA sequence. OVA wild-type DNA as well as the P30-modified OVA DNA vaccines (OVA-P30) were constructed and used for immunization in the OVA-transgenic mouse strains as well as in control C57Bl/6 mice. The data show that insertion of a foreign T-helper peptide (P30) in OVA is sufficient for breaking B-cell tolerance in three different OVA-transgenic mice strain. This approach is sufficient for induction of self-reactive CTL in two of the three strains that expressed either a membrane-bound form of OVA or a low amount of soluble OVA. It was not possible to induce CTL but still possible to induce autoantibodies in the strain that expressed a higher level of soluble OVA.

References

Aug 1, 1992·The Journal of Experimental Medicine·S Guerder, P Matzinger
Aug 1, 1993·European Journal of Immunology·J KirbergH von Boehmer
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·C C Goodnow
Dec 1, 1996·Current Opinion in Immunology·J F Miller, A Basten
Sep 1, 1996·The Journal of Experimental Medicine·R D CardinP C Doherty
Sep 1, 1996·The Journal of Experimental Medicine·C KurtsH Kosaka
Jul 7, 1997·The Journal of Experimental Medicine·S R BennettW R Heath
Jul 15, 1999·Nature Biotechnology·I DalumS Mouritsen
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·C KurtsW R Heath
Jun 6, 2000·The Journal of Experimental Medicine·D Nemazee, M Weigert
Jun 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J K SandbergK Kärre
Sep 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M HertzA Gautam
Sep 5, 2002·European Journal of Immunology·Christine BourgeoisCorinne Tanchot
Feb 21, 2003·Nature·Edith M JanssenStephen P Schoenberger
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Valéry RenardDana R Leach
Dec 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jyh-Chiang E Wang, Alexandra M Livingstone
Mar 17, 2004·The Journal of Experimental Medicine·Emmanuelle GaudinAntónio A Freitas
Jun 11, 2005·Cancer Immunology, Immunotherapy : CII·Constantin N BaxevanisMichael Papamichail
Jun 24, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lucilla SteinaaAnand M Gautam
Jul 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Keli L HippenTimothy W Behrens
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Satoko MatsuedaMamoru Harada
Mar 25, 2006·Future Oncology·Fortunato Ciardiello
Feb 21, 2007·Scandinavian Journal of Immunology·L SteinaaA Gautam

❮ Previous
Next ❯

Citations

Jul 20, 2010·Immunotherapy·Alexander Link, Martin F Bachmann
Apr 21, 2010·European Journal of Immunology·Mariam NasreenRaymond J Steptoe
Feb 8, 2019·Proceedings of the National Academy of Sciences of the United States of America·Christopher A ParksLarry R Pease
Sep 5, 2008·Expert Review of Vaccines·Angela M Bodles-Brakhop, Ruxandra Draghia-Akli
Dec 26, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lars T van der VekenMirjam H M Heemskerk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.